Rotavirus vaccine RIX4414 (Rotarix™): A pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries

PharmacoEconomics

Volumn 29, Issue 11, 2011, Pages 989-1009

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Children; Gastroenteritis, prevention; Infants; RIX 4414, therapeutic use; Rotavirus infections, prevention

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

ANOREXIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEVELOPING COUNTRY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; IRRITABILITY; LOWEST INCOME GROUP; MIDDLE INCOME GROUP; MORBIDITY; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHINORRHEA; ROTAVIRUS GASTROENTERITIS; SIDE EFFECT; SOCIOECONOMICS; VACCINATION; VIRAL GASTROENTERITIS; VOMITING;

CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; GASTROENTERITIS; HEALTH CARE COSTS; HUMANS; MASS VACCINATION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 80054116968     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11207210-000000000-00000     Document Type: Article

References (116)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9 (5): 565-72 (Pubitemid 36529515)
2. Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22 (5): 476-87 (Pubitemid 43130865)
3. Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecomm Rep 2009 Feb 6; 58 (RR-2): 1-25
4. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRRecomm Rep 2006 Aug 11; 55 (RR-12): 1-13
5. Gray J, Vesikari T, Van Damme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S24-31 (Pubitemid 351644167)
6. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004 Aug; 33 (8): 536-43 (Pubitemid 39079062)
7. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25 Suppl. 1: S7-11 (Pubitemid 43884460)
8. Grimwood K, Lambert SB,Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Pediatr Drugs 2010; 12 (4): 235-56
9. Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304-6
10. Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S54-6
11. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29-56 (Pubitemid 40070041)
12. Diez-Domingo J, Baldo J-M, Patrzalek M, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011 Feb; 170 (2): 213-22
13. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl. 1: S4-16
14. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996 Oct 3; 335 (14): 1022-8 (Pubitemid 26338732)
15. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993 Aug; 168 (2): 282-7 (Pubitemid 23210600)
16. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983 Jul 14; 309 (2): 72-6 (Pubitemid 13063589)
17. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38-48 (Pubitemid 351644169)
18. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009 May; 123 (5): 1412-20
19. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 615-8
20. Global Advisory Committee on Vaccine Safety. Report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; 84 (32): 325-32
21. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009 Jun 5; 84: 220-35
22. World Health Organization. Global use of rotavirus vaccines recommended [media release; online]. Available from URL: http://www.who.int/mediacentre/ news/releases/2009/rotavirus-vaccines-20090605/en/index.html# [Accessed 2011 May 24]
23. McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix™): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009; 11 (1): 75-88
24. Plosker GL. Pentavalent rotavirus vaccine (RotaTeq®): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010 Jun 18; 70 (9): 1165-88
25. Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28 (12): 1069-74
26. Shafie AA, Hassali MA. Is there a role for pharmacoeconomics in developing countries? [letter; author reply 84-86]. Pharmacoeconomics 2011; 29 (1): 83-84
27. World Bank. World Bank list of economics (January 2011) [online]. Available from URL: http://siteresources.world bank.org/DATASTATISTICS/ Resources/CLASS.XLS [Accessed 2011 May 24]
28. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 2011; 29 (5): 439-54
29. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 Suppl. 1: S9-15
30. Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl JMed 2009; 361 (20): 1919-21
31. Tate JE, Chitambar S, Esposito DH, et al. Disease and economic burden of rotavirus diarrhoea in India. Vaccine 2009 Nov 20; 27 Suppl. 5: F18-24
32. Nelson EAS, Walker DG. Reaching MDG 4 in India: a role for rotavirus vaccine? Clin Infect Dis 2011; 52 (2): 178-9
33. Sanchez-Padilla E, Grais RF, Guerin PJ, et al. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis 2009 Sep; 9 (9): 567-76
34. Kiulia NM, Kamenwa R, Irimu G, et al. The epidemiology of human rotavirus associated with diarrhoea in Kenyan children: a review. J Trop Pediatr 2008 Dec; 54 (6): 401-5
35. de Oliveira LH, Danovaro-Holliday MC, Andrus JK, et al. Sentinel hospital surveillance for rotavirus in Latin American and Caribbbean countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S131-9
36. de Oliveira LH, Danovaro-Holliday MC, Matus CR, et al. Rotavirus vaccine introduction in theAmericas: progress and lessons learned. Expert Rev Vaccines 2008 Apr; 7 (3): 345-53 (Pubitemid 351520022)
37. Meszner Z, Balogh A, Banyai K, et al. The clinical burden of rotavirus disease: retrospective analysis of infant and childhood gastroenteritis in seven countries in central and eastern Europe. Pediatr Infect Dis J 2008; 27 Suppl. 1: S33-41
38. Ceyhan M, Alhan E, Salman N, et al. Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S234-8
39. Centenari C, Gurgel RQ, Bohland AK, et al. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine 2010; 28 (25): 4162-8
40. Granados-Garcia V, Velazquez-Castillo R, Garduno- Espinosa J, et al. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective. Rev Invest Clin 2009; 61 (1): 18-25
41. De la Hoz F, Alvis N, Narvaez J, et al. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010 May 14; 28 (22): 3856-64
42. Ehrenkranz P, Lanata CF, Penny ME, et al. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001 Oct; 10 (4): 240-8 (Pubitemid 33064131)
43. Rheingans RD, Constenla D, Antil L, et al. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007 Apr; 21 (4): 192-204 (Pubitemid 47147595)
44. Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. Int J Infect Dis 2010 Jul 1; 14 (7): e592-5
45. Aikins M, Armah G, Akazili J, et al. Hospital health care cost of diarrheal disease in Northern Ghana. J Infect Dis 2010 Sep 1; 202 Suppl.: S126-30
46. Tate JE, Kisakye A, Mugyenyi P, et al. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011 Jan 14; 29: 3329-34
47. Nelson EA, Bresee JS, Parashar UD, et al. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008 Jun 19; 26 (26): 3192-6
48. WiddowsonM-A, Steele D, Vojdani J, et al. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009; 200 Suppl. 1: S1-8
49. D'Souza RM, Hall G, Becker NG. Climatic factors associated with hospitalizations for rotavirus diarrhoea in children under 5 years of age. Epidemiol Infect 2008 Jan; 136 (1): 56-64
50. Levy K, Hubbard AE, Eisenberg JN. Seasonality of rotavirus disease in the tropics: a systematic review and metaanalysis. Int J Epidemiol 2009 Dec; 38 (6): 1487-96
51. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 5; 371 (9619): 1181-9 (Pubitemid 351458523)
52. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010 Jan 28; 362 (4): 289-98
53. Ruiz-PalaciosGM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan; 354 (1): 11-22 (Pubitemid 43048947)
54. Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30 (6): e103-8
55. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22 (3): 259-67
56. Soares-Weiser K, Maclehose H, Ben-Aharon I, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2010; 5: CD008521
57. DeVos B, Vesikari T, Linhares AC, et al.Arotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004 Oct; 23 (10 Suppl.): S179-82 (Pubitemid 44146429)
58. Salinas B, Perez Schaeil I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebocontrolled trial in Latin American infants. Pediatr Infect Dis J 2005 Sep; 24 (9): 807-16 (Pubitemid 41324890)
59. Gurgel RG, Bohland AK, Vieira SC, et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009 Dec; 137 (6): 1970-5
60. Richardson V, Hernandez-Pichardo J, Quintanar-SolaresM, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl JMed 2010 Jan 28; 362 (4): 299-305
61. Quintanar-Solares M, Yen C, Richardson V, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S11-5
62. Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S6-10
63. dePalmaO, CruzL, RamosH, et al. Effectivenessof rotavirus vaccination against childhood diarrhoea in El Salvador: casecontrol study. BMJ 2010 Jun 15; 340: c2825
64. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010 Feb 1; 201 (3): 363-9
65. GlaxoSmithKline. Rotarix (rotavirus vaccine, live, oral) US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2011 Feb
66. GlaxoSmithKline Biologicals s.a.. Rotarix™ EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000639/WC500054789.pdf [Accessed 2011 Mar 14]
67. Atherly D, Dreibelbis R, Parashar UD, et al. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S28-38
68. Berry SA, Johns B, Shih C, et al. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010 Sep; 202 Suppl.: S108-15
69. Clark AD, Walker DG, Mosqueira NR, et al. Costeffectiveness of rotavirus vaccination in Peru. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S114-24
70. Constenla DO, Linhares AC, Rheingans RD, et al. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008 Dec; 26 (4): 388-96
71. Constenla D, Velazquez FR, Rheingans RD, et al. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009 Jun; 25 (6): 481-90
72. Esposito DH, Tate JE, Kang G, et al. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011; 52 (2): 171-7
73. Podewils LJ, Antil L, Hummelman E, et al. Projected costeffectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005 Sep 1; 192 Suppl. 1: S133-45 (Pubitemid 41193115)
74. Ortega O, El-Sayed N, Sanders JW, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S92-8
75. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010 Jan; 41 (1): 114-25
76. Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007 Jan 4; 25 (2): 373-80 (Pubitemid 44856079)
77. Tate JE, Rheingans RD, O'Reilly CE, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S76-84
78. Wang XY, Riewpaiboon A, von Seidlein L, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009 Oct 15; 49 (8): 1202-10
79. de Soárez PC, Valentim J, Sartori AM, et al. Costeffectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008 Apr; 23 (4): 221-30
80. Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005 Nov 15; 192 (10): 1720-6
81. Flem ET, Latipov R, Nurmatov ZS, et al. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S195-202
82. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009; 9: 29
83. Rheingans RD, Antil L,Dreibelbis R, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S16-27
84. Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009; 339: b3653
85. Wilopo SA, Kilgore P, Kosen S, et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009 Nov 20; 27 Suppl. 5: F67-74
86. Kim SY, Sweet S, Slichter D, et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010; 10: 253
87. Murray CJL, Lopez AD. The global burden of disease. Vol. I of global burden of disease and injury series. Cambridge (MA): Harvard University Press, 1996
88. Meeting of the Immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009; 84 (23): 220-36
89. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003 Apr; 17 (8): 1021-30 (Pubitemid 36560802)
90. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006 Jan 5; 354 (1): 23-33 (Pubitemid 43048948)
91. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009; 84: 533-40
92. Bernstein DI, Sack DA, Reisinger K, et al. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002 Nov 15; 186 (10): 1487-9 (Pubitemid 35286118)
93. Rotavirus vaccine - AVANT immunotherapeutics/Glaxo- SmithKline: 89-12, RIX4414. Drugs R D 2004; 5: 113-5
94. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23 (10): 937-43 (Pubitemid 40812781)
95. World Health Organization. Some strategies to reduce risk. In: WHO. The world health report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002 [online]. Available from URL: http://www.who.int/whr/2002/en/ [Accessed 2011 Jun 28]
96. World Bank. World development report 1993: investing in health. Washington, DC: Oxford University Press, 1993
97. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191-215 (Pubitemid 351271379)
98. Bauch CT, Anonychuk AM, Van Effelterre T, et al. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009; 29 (5): 557-69
99. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23 (1): 76-82 (Pubitemid 36133362)
100. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434-46 (Pubitemid 44410295)
101. Mangen MJ, van Duynhoven YT, Vennema H, et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010 Mar 19; 28 (14): 2624-35
102. Jit M, Bilcke J,Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009 Oct 19; 27 (44): 6121-8
103. de Blasio BF, Kasymbekova K, Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 2010 Nov 23; 28 (50): 7923-32
104. Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009 Jun 19; 27 (30): 4025-30
105. Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009 Jul 17; 325 (5938): 290-4
106. World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes [online]. Available from URL: http://www.who.int/immunization-financing/tools/who-ivb-08-14-en.pdf [Accessed 2011 Sep 6]
107. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S1-5
108. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S56-60
109. Monto AS. Epidemiology of influenza. Vaccine 2008 Sep 12; 26 Suppl. 4: D45-8
110. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity: United States, July 2007- December 2008. MMWR Morb Mortal Wkly Rep 2008 Dec 19; 57 (50): 1355-8
111. Tu HA, Woerdenbag HJ, Kane S, et al. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines 2011; 10 (7): 1037-51
112. Postma MJ, Jit M, Rozenbaum MH, et al. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs: a generic approach applied to various regions in the world. BMC Med 2011; 9: 84
113. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, et al. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8: 103
114. Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27 (11): 903-17
115. GAVI. GAVI welcomes lower prices for life-saving vaccines: manufacturer commitments will help GAVI vaccinate millions of children in least-developed countries [media release]. 2011 Jun 6 [online]. Available from URL: http://www.gavialliance.org/library/news/press-releases/ 2011/gavi-welcomes- lower-prices-for-life-saving-vaccines/ [Accessed 2011 Sep 2]
116. Connolly M, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. In press.